---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-037994"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:44:18.556494+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology Q2 net loss $37.2M; ziftomenib registration trial enrollment beats projections

## Summary
- Q2 2023 net loss $37.2M vs $34.8M in Q2 2022; R&D expenses $28.2M (up from $24.3M).
- Cash, equivalents & investments $477M at June 30, 2023; includes $93.6M net from June offering; runway to mid-2026.
- Ziftomenib in NPM1-mutant AML: CR rate 35% at 600 mg RP2D; registration-directed trial (85 pts) enrollment ahead of projections.
- Combination study KOMET-007 (ziftomenib + ven/aza or 7+3) now dosing patients; preliminary data expected Q4 2023 or Q1 2024.
- Next-gen FTI KO-2806 Phase 1 FIT-001 trial to begin dosing in H2 2023; tipifarnib+alpelisib in HNSCC at highest planned dose cohort.

## SEC filing metadata
- accession: 0000950170-23-037994
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000095017023037994/0000950170-23-037994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000095017023037994/kura-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-037994
- JSON: https://secwatch.observer/filing/0000950170-23-037994.json
- Plain text: https://secwatch.observer/filing/0000950170-23-037994.txt

## Key facts
- Earnings Releases
  Kura Oncology, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 3, 2023, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the second quarter ended June 30, 2023 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000095017023037994/0000950170-23-037994-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.